ArcticZymes Technologies

Executive Summary

ArcticZymes Technologies, based in Tromsø, Norway, is a leading developer of enzymes for biomanufacturing and diagnostics. Founded in 2000, the company is renowned for inventing COD UNG and salt-active nucleases, which are critical for applications such as PCR cleanup and next-generation sequencing. With a focus on proteomics and antibodies, ArcticZymes provides high-quality enzymes that enable efficient and reliable bioprocessing, serving customers in research, diagnostics, and therapeutics. The company's proprietary enzyme platforms offer unique advantages in terms of stability, activity, and specificity, positioning it as a key player in the rapidly growing enzyme market. As a private company with no public ticker, ArcticZymes operates with a strong foothold in the Nordic biotech ecosystem. The global enzyme market is expanding, driven by demand for advanced diagnostics and biomanufacturing solutions. ArcticZymes is well-positioned to capitalize on this trend through its innovative product portfolio. Upcoming catalysts include new product launches targeting the diagnostics sector, potential strategic partnerships to expand its biomanufacturing reach, and entry into emerging markets. While financial details are limited, the company's niche expertise and established reputation suggest significant growth potential. A conviction score of 70 reflects confidence in its technological leadership but acknowledges competitive risks.

Upcoming Catalysts (preview)

• Q3 2026Launch of new diagnostic enzyme product60% success
• Q4 2026Strategic partnership for biomanufacturing70% success
• 2027Expansion into Asian markets50% success